DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
6532
S-1360
2
Small molecule
Investigational
Unknown
Unknown
HIV Infections
Human immunodeficiency virus type 1 integrase inhibitor
S-1360
×
Maximum Phase:
2
First Approval:
None
UNII:
W7KQU075CV
Molecule Type:
Small molecule
Molecular Formula:
C16H12FN3O3
Molecular Weight:
313.29
AlogP:
2.91
PSA:
92.01
HBD:
2.0
HBA:
#RotB:
5.0
Source:
THYMIDINE
2
Small molecule
Investigational
Unknown
Unknown
Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms
Unknown
THYMIDINE
×
Maximum Phase:
2
First Approval:
None
UNII:
VC2W18DGKR
Molecule Type:
Small molecule
Molecular Formula:
C10H14N2O5
Molecular Weight:
242.23
AlogP:
-1.51
PSA:
104.55
HBD:
3.0
HBA:
#RotB:
2.0
Source:
GSK-1292263
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2; Lipid Metabolism Disorders
Glucose-dependent insulinotropic receptor agonist
GSK-1292263
×
Maximum Phase:
2
First Approval:
None
UNII:
R1J57STA6O
Molecule Type:
Small molecule
Molecular Formula:
C23H28N4O4S
Molecular Weight:
456.57
AlogP:
3.95
PSA:
98.42
HBD:
0.0
HBA:
#RotB:
7.0
Source:
R-348
2
Small molecule
Investigational
Unknown
Unknown
Dry Eye Syndromes; Graft vs Host Disease
Tyrosine-protein kinase JAK3 inhibitor
R-348
×
Maximum Phase:
2
First Approval:
None
UNII:
3J396119JY
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LUCANTHONE HYDROCHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Glioblastoma
Unknown
LUCANTHONE HYDROCHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
918K9N56QZ
Molecule Type:
Small molecule
Molecular Formula:
C20H25ClN2OS
Molecular Weight:
376.95
AlogP:
4.48
PSA:
32.34
HBD:
1.0
HBA:
#RotB:
6.0
Source:
ACEBILUSTAT
2
Small molecule
Investigational
Unknown
Unknown
Acne Vulgaris; Cystic Fibrosis; Severe Acute Respiratory Syndrome
Leukotriene A4 hydrolase inhibitor
ACEBILUSTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
J64RI4D29U
Molecule Type:
Small molecule
Molecular Formula:
C29H27N3O4
Molecular Weight:
481.55
AlogP:
5.29
PSA:
79.04
HBD:
1.0
HBA:
#RotB:
8.0
Source:
LJN452
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
LJN452
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SERALUTINIB
2
Small molecule
Investigational
Unknown
Unknown
Hypertension, Pulmonary
Unknown
SERALUTINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C27H27N5O3
Molecular Weight:
469.55
AlogP:
5.29
PSA:
98.26
HBD:
2.0
HBA:
#RotB:
8.0
Source:
IBODUTANT
2
Small molecule
Investigational
Unknown
Unknown
Irritable Bowel Syndrome
Neurokinin 2 receptor antagonist
IBODUTANT
×
Maximum Phase:
2
First Approval:
None
UNII:
1H7RSQ28BJ
Molecule Type:
Small molecule
Molecular Formula:
C37H48N4O4S
Molecular Weight:
644.88
AlogP:
5.23
PSA:
99.77
HBD:
3.0
HBA:
#RotB:
11.0
Source:
DP001
2
Small molecule
Investigational
Unknown
Unknown
Osteoporosis, Postmenopausal; Hyperparathyroidism, Secondary; Osteoporosis
Vitamin D receptor agonist
DP001
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C27H44O3
Molecular Weight:
416.65
AlogP:
5.7
PSA:
60.69
HBD:
3.0
HBA:
#RotB:
6.0
Source:
3,5-DIIODOTHYROPROPIONIC ACID
2
Small molecule
Investigational
Unknown
Unknown
Hypercholesterolemia; Heart Failure
Unknown
3,5-DIIODOTHYROPROPIONIC ACID
×
Maximum Phase:
2
First Approval:
None
UNII:
1HTO2X0SJ9
Molecule Type:
Small molecule
Molecular Formula:
C15H12I2O4
Molecular Weight:
510.07
AlogP:
4.41
PSA:
66.76
HBD:
2.0
HBA:
#RotB:
5.0
Source:
MIRAMISTIN ION
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
MIRAMISTIN ION
×
Maximum Phase:
2
First Approval:
None
UNII:
62S6VPY15U
Molecule Type:
Small molecule
Molecular Formula:
C26H47N2O+
Molecular Weight:
403.68
AlogP:
6.47
PSA:
29.1
HBD:
1.0
HBA:
#RotB:
18.0
Source:
FOSDAGROCORAT
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid
Glucocorticoid receptor modulator
FOSDAGROCORAT
×
Maximum Phase:
2
First Approval:
None
UNII:
HPI19004QS
Molecule Type:
Small molecule
Molecular Formula:
C29H30F3N2O5P
Molecular Weight:
574.54
AlogP:
6.28
PSA:
108.75
HBD:
3.0
HBA:
#RotB:
6.0
Source:
TRIDECANOATE
2
Small molecule
Investigational
Unknown
Unknown
Rett Syndrome
Unknown
TRIDECANOATE
×
Maximum Phase:
2
First Approval:
None
UNII:
19936LIY2V
Molecule Type:
Small molecule
Molecular Formula:
C13H26O2
Molecular Weight:
214.35
AlogP:
4.38
PSA:
37.3
HBD:
1.0
HBA:
#RotB:
11.0
Source:
OLTIPRAZ
2
Small molecule
Investigational
Unknown
Unknown
Lung Neoplasms; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease
Unknown
OLTIPRAZ
×
Maximum Phase:
2
First Approval:
None
UNII:
6N510JUL1Y
Molecule Type:
Small molecule
Molecular Formula:
C8H6N2S3
Molecular Weight:
226.35
AlogP:
3.3
PSA:
25.78
HBD:
0.0
HBA:
#RotB:
1.0
Source:
AMA0076
2
Small molecule
Investigational
Unknown
Unknown
Glaucoma; Ocular Hypertension
Rho-associated protein kinase inhibitor
AMA0076
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PYROPHOSPHORIC ACID
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
PYROPHOSPHORIC ACID
×
Maximum Phase:
2
First Approval:
None
UNII:
4E862E7GRQ
Molecule Type:
Small molecule
Molecular Formula:
H4O7P2
Molecular Weight:
177.97
AlogP:
-0.81
PSA:
124.29
HBD:
4.0
HBA:
#RotB:
2.0
Source:
ANTIMONY
2
Small molecule
Investigational
Unknown
Unknown
Leishmaniasis, Cutaneous
Unknown
ANTIMONY
×
Maximum Phase:
2
First Approval:
None
UNII:
9IT35J3UV3
Molecule Type:
Small molecule
Molecular Formula:
Sb
Molecular Weight:
121.76
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
MITOQUINONE CATION
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
MITOQUINONE CATION
×
Maximum Phase:
2
First Approval:
None
UNII:
47BYS17IY0
Molecule Type:
Small molecule
Molecular Formula:
C37H44O4P+
Molecular Weight:
583.73
AlogP:
7.46
PSA:
52.6
HBD:
0.0
HBA:
#RotB:
16.0
Source:
BRANEBRUTINIB
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid
Tyrosine-protein kinase BTK inhibitor
BRANEBRUTINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
7LBRZUYSHU
Molecule Type:
Small molecule
Molecular Formula:
C20H23FN4O2
Molecular Weight:
370.43
AlogP:
2.13
PSA:
91.22
HBD:
3.0
HBA:
#RotB:
3.0
Source:
HYDROXYTYROSOL
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms
Unknown
HYDROXYTYROSOL
×
Maximum Phase:
2
First Approval:
None
UNII:
QEU0NE4O90
Molecule Type:
Small molecule
Molecular Formula:
C9H12O3
Molecular Weight:
168.19
AlogP:
1.02
PSA:
60.69
HBD:
3.0
HBA:
#RotB:
3.0
Source:
ROBALZOTAN
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Serotonin 1a (5-HT1a) receptor antagonist
ROBALZOTAN
×
Maximum Phase:
2
First Approval:
None
UNII:
I18M56OGME
Molecule Type:
Small molecule
Molecular Formula:
C18H23FN2O2
Molecular Weight:
318.39
AlogP:
2.64
PSA:
55.56
HBD:
1.0
HBA:
#RotB:
4.0
Source:
SOTICLESTAT
2
Small molecule
Investigational
Unknown
Unknown
Epilepsy; Complex Regional Pain Syndromes; Epilepsies, Myoclonic; Lennox Gastaut Syndrome
Cholesterol 24-hydroxylase inhibitor
SOTICLESTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
1766MU795L
Molecule Type:
Small molecule
Molecular Formula:
C23H23N3O2
Molecular Weight:
373.46
AlogP:
3.35
PSA:
66.32
HBD:
1.0
HBA:
#RotB:
4.0
Source:
PX-102
2
Small molecule
Investigational
Unknown
Unknown
Non-alcoholic Fatty Liver Disease
Bile acid receptor FXR agonist
PX-102
×
Maximum Phase:
2
First Approval:
None
UNII:
378SU5NO8S
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
INCB-40093
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Hodgkin Disease
PI3-kinase p110-delta subunit inhibitor
INCB-40093
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BMS-223131
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Calcium-activated potassium channel subunit alpha-1 activator
BMS-223131
×
Maximum Phase:
2
First Approval:
None
UNII:
889F719S7K
Molecule Type:
Small molecule
Molecular Formula:
C18H13ClF3NO3
Molecular Weight:
383.75
AlogP:
4.11
PSA:
73.32
HBD:
3.0
HBA:
#RotB:
3.0
Source:
ORVEPITANT
2
Small molecule
Investigational
Unknown
Unknown
Depressive Disorder; Depressive Disorder, Major; Stress Disorders, Post-Traumatic
Neurokinin 1 receptor antagonist
ORVEPITANT
×
Maximum Phase:
2
First Approval:
None
UNII:
IIU6V0W3JD
Molecule Type:
Small molecule
Molecular Formula:
C31H35F7N4O2
Molecular Weight:
628.63
AlogP:
6.8
PSA:
47.1
HBD:
0.0
HBA:
#RotB:
4.0
Source:
.ALPHA.-R-LIPOIC ACID CHOLINE ESTER CHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Presbyopia
Unknown
.ALPHA.-R-LIPOIC ACID CHOLINE ESTER CHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
6HBG94710Z
Molecule Type:
Small molecule
Molecular Formula:
C13H26ClNO2S2
Molecular Weight:
327.94
AlogP:
2.95
PSA:
26.3
HBD:
0.0
HBA:
#RotB:
8.0
Source:
D-ASPARTATE
2
Small molecule
Investigational
Unknown
Unknown
Brain Injuries; Multiple Sclerosis, Relapsing-Remitting
Unknown
D-ASPARTATE
×
Maximum Phase:
2
First Approval:
None
UNII:
4SR0Q8YD1X
Molecule Type:
Small molecule
Molecular Formula:
C4H7NO4
Molecular Weight:
133.1
AlogP:
-1.13
PSA:
100.62
HBD:
3.0
HBA:
#RotB:
3.0
Source:
LANIQUIDAR
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms
Unknown
LANIQUIDAR
×
Maximum Phase:
2
First Approval:
None
UNII:
K3FRN4DDOY
Molecule Type:
Small molecule
Molecular Formula:
C37H36N4O3
Molecular Weight:
584.72
AlogP:
6.49
PSA:
69.48
HBD:
0.0
HBA:
#RotB:
7.0
Source:
BRADANICLINE
2
Small molecule
Investigational
Unknown
Unknown
Attention Deficit Disorder with Hyperactivity; Cough; Schizophrenia
Neuronal acetylcholine receptor protein alpha-7 subunit agonist
BRADANICLINE
×
Maximum Phase:
2
First Approval:
None
UNII:
UM3821998K
Molecule Type:
Small molecule
Molecular Formula:
C22H23N3O2
Molecular Weight:
361.45
AlogP:
3.26
PSA:
58.37
HBD:
1.0
HBA:
#RotB:
4.0
Source:
BAFETINIB
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Lymphocytic, Chronic, B-Cell; Prostatic Neoplasms, Castration-Resistant
Tyrosine-protein kinase ABL inhibitor
BAFETINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
NVW4Z03I9B
Molecule Type:
Small molecule
Molecular Formula:
C30H31F3N8O
Molecular Weight:
576.63
AlogP:
5.39
PSA:
99.17
HBD:
2.0
HBA:
#RotB:
8.0
Source:
THK-5351
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
THK-5351
×
Maximum Phase:
2
First Approval:
None
UNII:
JE3F6WUN31
Molecule Type:
Small molecule
Molecular Formula:
C18H18FN3O2
Molecular Weight:
327.36
AlogP:
3.05
PSA:
67.27
HBD:
2.0
HBA:
#RotB:
6.0
Source:
DOLASTATIN-10
2
Small molecule
Investigational
Unknown
Unknown
Myelodysplastic Syndromes; Gallbladder Neoplasms; Kidney Neoplasms; Leukemia; Lymphoma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Sarcoma
Tubulin inhibitor
DOLASTATIN-10
×
Maximum Phase:
2
First Approval:
None
UNII:
EI946JT51X
Molecule Type:
Small molecule
Molecular Formula:
C42H68N6O6S
Molecular Weight:
785.11
AlogP:
5.19
PSA:
133.41
HBD:
2.0
HBA:
#RotB:
21.0
Source:
TRETAZICAR
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Hepatocellular
Unknown
TRETAZICAR
×
Maximum Phase:
2
First Approval:
None
UNII:
7865D5D01M
Molecule Type:
Small molecule
Molecular Formula:
C9H8N4O5
Molecular Weight:
252.19
AlogP:
0.42
PSA:
132.38
HBD:
1.0
HBA:
#RotB:
4.0
Source:
1
2
…
95
96
97
98
99
100
101
…
186
187
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA